Covidien (NYSE: COV) and Hill-Rom (NYSE:HRC) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, dividends, analyst recommendations, earnings, profitability and risk.
Risk and Volatility
Covidien has a beta of 1.01, meaning that its share price is 1% more volatile than the S&P 500. Comparatively, Hill-Rom has a beta of 1.05, meaning that its share price is 5% more volatile than the S&P 500.
Institutional and Insider Ownership
81.2% of Hill-Rom shares are owned by institutional investors. 1.9% of Hill-Rom shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Valuation & Earnings
This table compares Covidien and Hill-Rom’s revenue, earnings per share (EPS) and valuation.
||Earnings Per Share
Hill-Rom has higher revenue and earnings than Covidien. Covidien is trading at a lower price-to-earnings ratio than Hill-Rom, indicating that it is currently the more affordable of the two stocks.
This table compares Covidien and Hill-Rom’s net margins, return on equity and return on assets.
||Return on Equity
||Return on Assets
This is a breakdown of current recommendations for Covidien and Hill-Rom, as provided by MarketBeat.
||Strong Buy Ratings
Hill-Rom has a consensus price target of $94.86, suggesting a potential upside of 14.41%. Given Hill-Rom’s higher possible upside, analysts plainly believe Hill-Rom is more favorable than Covidien.
Hill-Rom pays an annual dividend of $0.72 per share and has a dividend yield of 0.9%. Covidien does not pay a dividend. Hill-Rom pays out 24.5% of its earnings in the form of a dividend. Covidien has increased its dividend for 7 consecutive years.
Hill-Rom beats Covidien on 9 of the 14 factors compared between the two stocks.
Covidien Company Profile
Covidien Public Limited Company is a healthcare products company. The Company is engaged in the development, manufacture and sale of healthcare products for use in clinical and home settings. The Company’s brands include Kendall, Nellcor, Puritan Bennett and Valleylab, among others. It has a presence in more than 70 countries, with products sold in over 150 countries. The Company’s segments include Medical Devices and United States Medical Supplies. Medical Devices includes marketing of advanced and general surgical solutions, peripheral vascular and neurovascular therapies, patient monitoring products, and airway and ventilation products. United States Medical Supplies includes products, such as nursing care, medical surgical, SharpSafety and original equipment manufacturer (OEM) products. The Company’s products include Surgical Solutions, Vascular Therapies, Respiratory and Patient Care.
Hill-Rom Company Profile
Hill-Rom Holdings, Inc. is a global medical technology company. The Company operates through four segments: North America Patient Support Systems, International Patient Support Systems, Front Line Care and Surgical Solutions. The Company’s products and services include Patient Support Systems, Front Line Care and Surgical Solutions. The Company sells and rents its specialty frames and surfaces, and mobility solutions, as well as its clinical workflow solutions, in the United States and Canada through its North America Patient Support Systems segment, and in regions outside of the United States and Canada through its International Patient Support Systems segment. Its Front Line Care segment globally sells and rents respiratory care products, and sells medical diagnostic equipment and a diversified portfolio of devices that assess, diagnose, treat and manage a range of illnesses and diseases. Under its Surgical Solutions segment, the Company sells its surgical products globally.
Receive News & Ratings for Covidien Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Covidien and related companies with MarketBeat.com's FREE daily email newsletter.